Apr 26, 2024, 09:26
Chul Kim: Thoughtful discussion and great talk by Rachel Sanborn about recent approval of FLAURA2
Chul Kim, Thoracic Medical Oncologist at Georgetown University, shared a post on X/Twitter:
”First-line treatment for EGFR mutant NSCLC is getting complex with recent approval of FLAURA2.
Would higher risk populations benefit more (e.g. L858R, co-mutations including TP53, RB1, CNS met)?
Thoughtful discussion and great talk by Rachel Sanborn.”
Source: Chul Kim/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 24, 2024, 20:25
Oct 24, 2024, 20:14
Oct 24, 2024, 17:33